OVID
Price
$0.34
Change
+$0.01 (+3.03%)
Updated
Jul 3 closing price
Capitalization
24.06M
43 days until earnings call
RXRX
Price
$5.27
Change
+$0.06 (+1.15%)
Updated
Jul 3 closing price
Capitalization
2.14B
37 days until earnings call
Interact to see
Advertisement

OVID vs RXRX

Header iconOVID vs RXRX Comparison
Open Charts OVID vs RXRXBanner chart's image
Ovid Therapeutics
Price$0.34
Change+$0.01 (+3.03%)
Volume$283.19K
Capitalization24.06M
Recursion Pharmaceuticals
Price$5.27
Change+$0.06 (+1.15%)
Volume$16.58M
Capitalization2.14B
OVID vs RXRX Comparison Chart in %
Loading...
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
OVID vs. RXRX commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OVID is a StrongBuy and RXRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (OVID: $0.34 vs. RXRX: $5.27)
Brand notoriety: OVID and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OVID: 28% vs. RXRX: 65%
Market capitalization -- OVID: $24.06M vs. RXRX: $2.14B
OVID [@Biotechnology] is valued at $24.06M. RXRX’s [@Biotechnology] market capitalization is $2.14B. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OVID’s FA Score shows that 1 FA rating(s) are green whileRXRX’s FA Score has 0 green FA rating(s).

  • OVID’s FA Score: 1 green, 4 red.
  • RXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, both OVID and RXRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OVID’s TA Score shows that 5 TA indicator(s) are bullish while RXRX’s TA Score has 5 bullish TA indicator(s).

  • OVID’s TA Score: 5 bullish, 4 bearish.
  • RXRX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, RXRX is a better buy in the short-term than OVID.

Price Growth

OVID (@Biotechnology) experienced а -1.34% price change this week, while RXRX (@Biotechnology) price change was -2.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

OVID is expected to report earnings on Nov 12, 2025.

RXRX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($2.14B) has a higher market cap than OVID($24.1M). RXRX YTD gains are higher at: -22.041 vs. OVID (-63.757). OVID has higher annual earnings (EBITDA): -56.4M vs. RXRX (-524.77M). RXRX has more cash in the bank: 500M vs. OVID (43M). OVID has less debt than RXRX: OVID (14.4M) vs RXRX (92.9M). RXRX has higher revenues than OVID: RXRX (59.8M) vs OVID (548K).
OVIDRXRXOVID / RXRX
Capitalization24.1M2.14B1%
EBITDA-56.4M-524.77M11%
Gain YTD-63.757-22.041289%
P/E RatioN/AN/A-
Revenue548K59.8M1%
Total Cash43M500M9%
Total Debt14.4M92.9M16%
FUNDAMENTALS RATINGS
OVID: Fundamental Ratings
OVID
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
63
P/E GROWTH RATING
1..100
94
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
OVIDRXRX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
78%
Momentum
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
85%
MACD
ODDS (%)
Bullish Trend 4 days ago
79%
N/A
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
84%
Advances
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
84%
Declines
ODDS (%)
Bearish Trend 24 days ago
88%
Bearish Trend 14 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FSI5.540.14
+2.59%
Flexible Solutions International
RBCAA77.631.50
+1.97%
Republic Bancorp
DXLG1.200.02
+1.69%
Destination XL Group
CCI102.92-0.25
-0.24%
Crown Castle
HP16.42-0.14
-0.85%
Helmerich & Payne

OVID and

Correlation & Price change

A.I.dvisor indicates that over the last year, OVID has been closely correlated with JBIO. These tickers have moved in lockstep 79% of the time. This A.I.-generated data suggests there is a high statistical probability that if OVID jumps, then JBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OVID
1D Price
Change %
OVID100%
+2.39%
JBIO - OVID
79%
Closely correlated
+3.15%
BEAM - OVID
47%
Loosely correlated
+0.65%
ABOS - OVID
46%
Loosely correlated
+2.65%
RXRX - OVID
45%
Loosely correlated
+1.15%
CRNX - OVID
45%
Loosely correlated
+1.22%
More

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been closely correlated with CRSP. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if RXRX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
+1.15%
CRSP - RXRX
72%
Closely correlated
+0.97%
BEAM - RXRX
64%
Loosely correlated
+0.65%
ABSI - RXRX
63%
Loosely correlated
+2.97%
ABCL - RXRX
61%
Loosely correlated
+1.33%
PRME - RXRX
58%
Loosely correlated
+1.30%
More